Wegovy vs Mounjaro: Different Molecules, Different Approved Uses

They are different molecules from different manufacturers with different FDA-approved indications: Wegovy (semaglutide) for chronic weight management and Mounjaro (tirzepatide) for type 2 diabetes. Wegovy acts on the GLP-1 receptor; Mounjaro acts on both the GIP and GLP-1 receptors. Which one is appropriate for a given person is a clinical decision made by a licensed provider based on their individual medical profile.

FDA-approved indications and prescribing decisions differ between products, and Weight Method dispenses neither brand-name product. Whether a particular medication is appropriate for an individual is determined by a licensed provider based on that person's health profile and the applicable approved indication.

Cardiovascular considerations and overall suitability for any individual depend on that person's medical history and are evaluated by a licensed provider. Weight Method does not dispense either brand-name product and does not make comparative claims between them.

Both cause similar gastrointestinal side effects: nausea, vomiting, diarrhea, constipation, and decreased appetite. These are most common during dose titration and typically improve over several weeks. A licensed provider monitors tolerability for patients in Weight Method's compounded program.

Weight Method does not dispense or prescribe brand-name Wegovy® or Mounjaro®. Weight Method's compounded semaglutide program is $154/mo and compounded tirzepatide is $329/mo, dispensed by U.S.-licensed 503A compounding pharmacies. Each is a flat monthly rate covering medication, licensed provider oversight, and shipping. Compounded medications are not FDA-approved.